At 12 months, insulin therapy was an effective strategy in reducing HbA1c in a population with a very diverse duration of diabetes (SD 5–6 years), but the reduction of a little over 1.0% is somewhat disappointing compared with treat-to-target studies (14,25), despite similar insulin doses at 1 year. This evidence concerns the gene INS and diabetes mellitus.